Prostate Cancer Clinical Trial

Evaluation of a Targeted Magnetic Resonance Imaging Contrast Agent in Prostate Cancer Patients

Summary

This phase 1b open label, dose-escalating investigation study is to evaluate the dose dependent initial efficacy of the use of MT218 injection for biomarker targeted MR molecular imaging (MRMI) of prostate cancer in patients scheduled for radical prostatectomy.

View Full Description

Full Description

Phase 1b open label, single-arm, dose-escalating investigation of safety and efficacy of a gadolinium (Gd) and peptide based MRI contrast agent (MT218) as an extradomain-B fibronectin (EDB-FN) targeted molecular MR contrast agent to detect aggressive prostate cancer with comparison of its results with the standard-of-care mutliparametic MRI (mpMRI) and PSMA PET/CT and histopathology validation in preprostatectomy patients diagnosed with prostate cancer in their clinical care.

View Eligibility Criteria

Eligibility Criteria

Inclusion criteria

Male subjects aged >18 years.
Patients with confirmed Gleason score of 8 - 10 prostate cancer, had at least one prostate mpMRI and one prostate biopsy.
Ability to lie still for MRI scanning.
Patients must be able to provide written informed consent.
Glomerular filtration rate (GFR) > 60 mL/min within a 30 days of the research MRI.

Key exclusion criteria

Any diagnosis of active acute, chronic, or sub-chronic kidney or liver disease.
Documented acute prostatitis, symptomatic or severe benign prostatic hyperplasia (BPH) or urinary tract infections.
Patients with uncontrolled diabetes or hypertension.
Patients with active non-prostate malignancy.
Patients with contraindications for MRI including implantable pace makers, cochlear implants.
Patients with uni- or bilateral hip prosthesis.
Subjects with other significant medical conditions that would create unacceptable operative risk, compromise retention on study or compromise study related assessments.
Major surgery within 4 weeks prior to entry on this study or patients who have not recovered from side effects of such therapy.
Prostate biopsy within 4 weeks prior to entry on this study in which inflammation might affect MRI result.
Subjects who received or will receive any other MRI contrast agent within 48 hours prior to MT218 injection or up to 24 hours after MT218 injection.
Is determined by the investigator that the patient is clinically unsuitable for the study.
Is incapable of understanding the language in which the information for the patient is given.
Participation in a concurrent clinical trial or in another trial within the past 30 days.

Study is for people with:

Prostate Cancer

Phase:

Phase 1

Estimated Enrollment:

12

Study ID:

NCT06262139

Recruitment Status:

Not yet recruiting

Sponsor:

Molecular Theranostics LLC

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Emory University
Atlanta Georgia, 30322, United States

How clear is this clinincal trial information?

Study is for people with:

Prostate Cancer

Phase:

Phase 1

Estimated Enrollment:

12

Study ID:

NCT06262139

Recruitment Status:

Not yet recruiting

Sponsor:


Molecular Theranostics LLC

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.